Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6... Read More

WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer... Read More

WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024. On Wednesday, March 13, at 3:05 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical... Read More

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 clinical trial in second half of 2024 Recently established partnership with AbCellera to jointly discover, develop, and commercialize a portfolio of next generation precision ADCs... Read More

WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily... Read More

Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program being a SMARCA degrader-antibody conjugate Cash runway into 2026 with $230.5 million of cash, cash equivalents and marketable securities WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) --... Read More

WILMINGTON, Del. & VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer. The collaboration combines Prelude’s expertise in targeted protein degradation, medicinal... Read More

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four... Read More

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18 th Annual Healthcare Conference Boston Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday,... Read More

Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026, enabling advancement of Prelude’s pipeline through critical milestones WILMINGTON, Del., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended... Read More

WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 2023. Details are as follows: On Wednesday, June 7th, at 8:00 a.m. ET, Kris Vaddi, Ph.D., CEO of Prelude will participate in a fireside... Read More

WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222 shares of its non-voting common stock, each at a price to the public of $5.75 per share, and, in lieu of common stock to... Read More

WILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock. All of the shares of... Read More

Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and... Read More

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: H. C. Wainwright BioConnect Investor Conference at Nasdaq Kris Vaddi, Ph.D., Chief Executive Officer will participate in a fireside chat on... Read More

WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. “Prelude's six preclinical and two clinical abstracts being presented at the AACR Annual... Read More

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024 WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage... Read More

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies. Inhibition of BTK is an active therapeutic approach... Read More

WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023. On March 16, at 9:30 a.m. ET, Kris Vaddi, Ph.D., CEO of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in... Read More

WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40 a.m. ET , Kris Vaddi, Ph.D., Chief Executive Officer and Jane Huang, M.D., President and Chief Medical Officer, will participate in... Read More